Cancer Antigen (CA) 27.29
Also known as: CA 27.29 Antigen, Truquant BR
Use
Manage patients with metastatic carcinoma of the breast
Special Instructions
Values obtained with different assay methods should not be used interchangeably in serial testing. It is recommended to use the same assay method consistently for monitoring each patient's therapy. This test is intended for one-time use only. For serial monitoring, order test 480293.
Limitations
This test quantifies CA 27.29 antigen levels in the serum of patients previously treated for stage II or stage III breast cancer. It should be used alongside other clinical methods for early detection of recurrence. An elevated CA 27.29 level in patients in remission of stage II or III breast cancer can indicate a high probability of recurrence.
Methodology
Immunoassay (Immunochemiluminometric assay (ICMA))
Biomarkers
LOINC Codes
- 17842-6
- 17842-6
Result Turnaround Time
1 day
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.3 mL (Note: This volume does not allow for repeat testing.)
Container
Red-top tube or gel-barrier tube
Collection Instructions
If a red-top tube is used, transfer separated serum to a plastic transport tube.
Storage Instructions
Refrigerate.
Causes for Rejection
Plasma other than EDTA plasma
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 5 days |
| Frozen | >1 month |
Other tests from different labs that may be relevant